MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202521118777 A) filed by Dr. D. Y. Patil Institute Of Pharmaceutical Sciences And Research; School Of Pharmacy And Research; and Dr. Ritesh P. Bhole, Pune, Maharashtra, on Nov. 28, 2025, for 'pegylated moxifloxacin prodrugs for sustained release and macrophage-targeted tuberculosis treatment.'
Inventor(s) include Dr. Ritesh P. Bhole; Dr. H. S. Kapare; Dr. Sonali D. Labhade; and Mr. Pawan N. Karwa.
The application for the patent was published on Jan. 9, under issue no. 02/2026.
According to the abstract released by the Intellectual Property India: "The invention relates to polymer-drug conjugates comprising polyethylene glycol (PEG) covalently linked to an antimicrobial agent, exemplified by moxifloxacin, through a cleavable chemical linker designed to provide stability in systemic circulation and controlled release of active drug under intracellular or infection-site conditions. The conjugates are obtained by activating PEG to form an activated ester or carbonate intermediate, coupling the activated PEG with the antibiotic under controlled conditions, and purifying the resulting product by extraction, dialysis, ultrafiltration or chromatographic techniques. The PEG-moxifloxacin conjugates exhibit modulated drug loading, improved solubility and sustained-release characteristics, and are suitable for formulation into parenteral, oral, inhalable or depot dosage forms. Pharmaceutical compositions containing the conjugates and methods of treating tuberculosis and related mycobacterial infections by administering an effective amount of the conjugate are also provided. The invention further encompasses variations in PEG architecture, linker chemistry and targeting ligands to enhance intracellular and macrophage-specific delivery of the antimicrobial agent."
Disclaimer: Curated by HT Syndication.
